EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data

Marc W H Lochmann van Bennekom, Joanna IntHout, Harm J Gijsman, Berna B K Akdede, A Elif Anıl Yağcıoğlu, Thomas R E Barnes, Britta Galling, Ralitza Gueorguieva, Siegfried Kasper, Anatoly Kreinin, Jimmi Nielsen, René Ernst Nielsen und 7 weitere

Schizophrenia Research · 2024

DOI: 10.1016/j.schres.2024.07.035 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Schizophrenia Research, 2024. Verfasst von Marc W H Lochmann van Bennekom und 18 weiteren Autor:innen. Beteiligte Einrichtung: Pro Persona Mental Health Care, Expertise Center for Depression, Nijmeegsebaan 61, 6525 DX Nijmegen, the Netherlands; Donders Institute for Brain, Co…. Hauptthemen laut MEDLINE: Antipsychotic Agents, Schizophrenia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Antipsychotic polypharmacy (APP) is frequently prescribed for schizophrenia-spectrum disorders. Despite the inconsistent findings on efficacy, APP may be beneficial for subgroups of psychotic patients. This meta-analysis of individual patient data investigated moderators of efficacy and tolerability of APP in adult patients with schizophrenia-spectrum disorders. DESIGN: We searched PubMed, EMBASE, and the Cochrane Central Register of Randomized Trials until September 1, 2022, for randomized controlled trials comparing APP with antipsychotic monotherapy. We estimated the effects with a one-stage approach for patient-level moderators and a two-stage approach for study-level moderators, using (generalized) linear mixed-effects models. Primary outcome was treatment response, defined as a reduction of 25 % or more in the Positive and Negative Syndrome Scale (PANSS) score. Secondary outcomes were study discontinuation, and changes from baseline on the PANSS total score, its positive and negative symptom subscale scores, the Clinical Global Impressions Scale (CGI), and adverse effects. RESULTS: We obtained individual patient data from 10 studies (602 patients; 31 % of all possible patients) and included 599 patients in our analysis. A higher baseline PANSS total score increased the chance of a response to APP (OR = 1.41, 95 % CI 1.02; 1.94, p = 0.037 per 10-point increase in baseline PANSS total), mainly driven by baseline positive symptoms. The same applied to changes on the PANSS positive symptom subscale and the CGI severity scale. Extrapyramidal side effects increased significantly where first and second-generation antipsychotics were co-prescribed. Study discontinuation was comparable between both treatment arms. CONCLUSIONS: APP was effective in severely psychotic patients with high baseline PANSS total scores and predominantly positive symptoms. This effect must be weighed against potential adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsSchizophreniaHumansDrug Therapy, CombinationOutcome Assessment, Health CarePsychotic DisordersRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Antipsychotic polypharmacyEffect moderatorsEfficacyTolerability

Substanzen

Antipsychotic Agents

Autor:innen und Institutionen

  • Pro Persona Mental Health Care, Expertise Center for Depression, Nijmeegsebaan 61, 6525 DX Nijmegen, the Netherlands; Donders Institute for Brain, Cognition, and Behaviour, Radboud University, Nijmegen, the Netherlands.…
  • Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Dimence Mental Healthcare, Deventer, the Netherlands.
  • Dokuz Eylul University Faculty of Medicine, Department of Psychiatry, Balçova, İzmir, Turkey.
  • Hacettepe University Faculty of Medicine, Department of Psychiatry, Sıhhiye, Ankara, Turkey.
  • Division of Psychiatry, Imperial College London, London, UK.

Zitieren

APA

Lochmann van Bennekom, M. W. H., IntHout, J., Gijsman, H. J., Akdede, B. B. K., Yağcıoğlu, A. E. A., Barnes, T. R. E., Galling, B., Gueorguieva, R., Kasper, S., Kreinin, A., Nielsen, J., Nielsen, R. E., Remington, G., Repo-Tiihonen, E., Schmidt-Kraepelin, C., Shafti, S. S., Xiao, L., Correll, C. U., & Verkes, R. J. (2024). Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data. Schizophrenia Research. https://doi.org/10.1016/j.schres.2024.07.035

Vancouver

Lochmann van Bennekom MWH, IntHout J, Gijsman HJ, Akdede BBK, Yağcıoğlu AEA, Barnes TRE, et al. Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data. Schizophrenia Research. 2024. doi:10.1016/j.schres.2024.07.035

BibTeX
@article{LochmannvanBennekom2024,
  author = {Lochmann van Bennekom, Marc W H and IntHout, Joanna and Gijsman, Harm J and Akdede, Berna B K and Yağcıoğlu, A Elif Anıl and Barnes, Thomas R E and Galling, Britta and Gueorguieva, Ralitza and Kasper, Siegfried and Kreinin, Anatoly and Nielsen, Jimmi and Nielsen, René Ernst and Remington, Gary and Repo-Tiihonen, Eila and Schmidt-Kraepelin, Christian and Shafti, Saeed S and Xiao, Le and Correll, Christoph U and Verkes, Robbert-Jan},
  title = {Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data},
  journal = {Schizophrenia Research},
  year = {2024},
  doi = {10.1016/j.schres.2024.07.035}
}
Kostenlos starten →